|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/16/19 Cannex Capital Holdings Inc. 40FR12G 138:29M Newsfile Corp/FA |
Document/Exhibit Description Pages Size 1: 40FR12G Registration of Securities of a Canadian Issuer HTML 112K 2: EX-99.1 Miscellaneous Exhibit -- exhibit99-1 HTML 53K 11: EX-99.10 Miscellaneous Exhibit -- exhibit99-10 HTML 30K 101: EX-99.100 Miscellaneous Exhibit -- exhibit99-100 HTML 49K 102: EX-99.101 Miscellaneous Exhibit -- exhibit99-101 HTML 872K 103: EX-99.102 Miscellaneous Exhibit -- exhibit99-102 HTML 78K 104: EX-99.103 Miscellaneous Exhibit -- exhibit99-103 HTML 70K 105: EX-99.104 Miscellaneous Exhibit -- exhibit99-104 HTML 35K 106: EX-99.105 Miscellaneous Exhibit -- exhibit99-105 HTML 2.88M 107: EX-99.106 Miscellaneous Exhibit -- exhibit99-106 HTML 34K 108: EX-99.107 Miscellaneous Exhibit -- exhibit99-107 HTML 33K 109: EX-99.108 Miscellaneous Exhibit -- exhibit99-108 HTML 39K 110: EX-99.109 Miscellaneous Exhibit -- exhibit99-109 HTML 290K 12: EX-99.11 Miscellaneous Exhibit -- exhibit99-11 HTML 156K 111: EX-99.110 Miscellaneous Exhibit -- exhibit99-110 HTML 133K 112: EX-99.111 Miscellaneous Exhibit -- exhibit99-111 HTML 33K 113: EX-99.112 Miscellaneous Exhibit -- exhibit99-112 HTML 33K 114: EX-99.113 Miscellaneous Exhibit -- exhibit99-113 HTML 42K 115: EX-99.114 Miscellaneous Exhibit -- exhibit99-114 HTML 32K 116: EX-99.115 Miscellaneous Exhibit -- exhibit99-115 HTML 39K 117: EX-99.116 Miscellaneous Exhibit -- exhibit99-116 HTML 34K 118: EX-99.117 Miscellaneous Exhibit -- exhibit99-117 HTML 37K 119: EX-99.118 Miscellaneous Exhibit -- exhibit99-118 HTML 455K 120: EX-99.119 Miscellaneous Exhibit -- exhibit99-119 HTML 133K 13: EX-99.12 Miscellaneous Exhibit -- exhibit99-12 HTML 30K 121: EX-99.120 Miscellaneous Exhibit -- exhibit99-120 HTML 33K 122: EX-99.121 Miscellaneous Exhibit -- exhibit99-121 HTML 33K 123: EX-99.122 Miscellaneous Exhibit -- exhibit99-122 HTML 41K 124: EX-99.123 Miscellaneous Exhibit -- exhibit99-123 HTML 36K 125: EX-99.124 Miscellaneous Exhibit -- exhibit99-124 HTML 491K 126: EX-99.125 Miscellaneous Exhibit -- exhibit99-125 HTML 140K 127: EX-99.126 Miscellaneous Exhibit -- exhibit99-126 HTML 33K 128: EX-99.127 Miscellaneous Exhibit -- exhibit99-127 HTML 33K 129: EX-99.128 Miscellaneous Exhibit -- exhibit99-128 HTML 30K 130: EX-99.129 Miscellaneous Exhibit -- exhibit99-129 HTML 492K 14: EX-99.13 Miscellaneous Exhibit -- exhibit99-13 HTML 32K 131: EX-99.130 Miscellaneous Exhibit -- exhibit99-130 HTML 143K 132: EX-99.131 Miscellaneous Exhibit -- exhibit99-131 HTML 32K 133: EX-99.132 Miscellaneous Exhibit -- exhibit99-132 HTML 32K 134: EX-99.133 Miscellaneous Exhibit -- exhibit99-133 HTML 30K 135: EX-99.134 Miscellaneous Exhibit -- exhibit99-134 HTML 69K 136: EX-99.135 Miscellaneous Exhibit -- exhibit99-135 HTML 31K 137: EX-99.136 Miscellaneous Exhibit -- exhibit99-136 HTML 29K 138: EX-99.137 Miscellaneous Exhibit -- exhibit99-137 HTML 30K 15: EX-99.14 Miscellaneous Exhibit -- exhibit99-14 HTML 32K 16: EX-99.15 Miscellaneous Exhibit -- exhibit99-15 HTML 32K 17: EX-99.16 Miscellaneous Exhibit -- exhibit99-16 HTML 33K 18: EX-99.17 Miscellaneous Exhibit -- exhibit99-17 HTML 34K 19: EX-99.18 Miscellaneous Exhibit -- exhibit99-18 HTML 42K 20: EX-99.19 Miscellaneous Exhibit -- exhibit99-19 HTML 33K 3: EX-99.2 Miscellaneous Exhibit -- exhibit99-2 HTML 31K 21: EX-99.20 Miscellaneous Exhibit -- exhibit99-20 HTML 45K 22: EX-99.21 Miscellaneous Exhibit -- exhibit99-21 HTML 145K 23: EX-99.22 Miscellaneous Exhibit -- exhibit99-22 HTML 77K 24: EX-99.23 Miscellaneous Exhibit -- exhibit99-23 HTML 32K 25: EX-99.24 Miscellaneous Exhibit -- exhibit99-24 HTML 32K 26: EX-99.25 Miscellaneous Exhibit -- exhibit99-25 HTML 35K 27: EX-99.26 Miscellaneous Exhibit -- exhibit99-26 HTML 28K 28: EX-99.27 Miscellaneous Exhibit -- exhibit99-27 HTML 38K 29: EX-99.28 Miscellaneous Exhibit -- exhibit99-28 HTML 34K 30: EX-99.29 Miscellaneous Exhibit -- exhibit99-29 HTML 782K 4: EX-99.3 Miscellaneous Exhibit -- exhibit99-3 HTML 28K 31: EX-99.30 Miscellaneous Exhibit -- exhibit99-30 HTML 30K 32: EX-99.31 Miscellaneous Exhibit -- exhibit99-31 HTML 49K 33: EX-99.32 Miscellaneous Exhibit -- exhibit99-32 HTML 31K 34: EX-99.33 Miscellaneous Exhibit -- exhibit99-33 HTML 51K 35: EX-99.34 Miscellaneous Exhibit -- exhibit99-34 HTML 35K 36: EX-99.35 Miscellaneous Exhibit -- exhibit99-35 HTML 36K 37: EX-99.36 Miscellaneous Exhibit -- exhibit99-36 HTML 42K 38: EX-99.37 Miscellaneous Exhibit -- exhibit99-37 HTML 36K 39: EX-99.38 Miscellaneous Exhibit -- exhibit99-38 HTML 38K 40: EX-99.39 Miscellaneous Exhibit -- exhibit99-39 HTML 35K 5: EX-99.4 Miscellaneous Exhibit -- exhibit99-4 HTML 30K 41: EX-99.40 Miscellaneous Exhibit -- exhibit99-40 HTML 35K 42: EX-99.41 Miscellaneous Exhibit -- exhibit99-41 HTML 35K 43: EX-99.42 Miscellaneous Exhibit -- exhibit99-42 HTML 35K 44: EX-99.43 Miscellaneous Exhibit -- exhibit99-43 HTML 36K 45: EX-99.44 Miscellaneous Exhibit -- exhibit99-44 HTML 31K 46: EX-99.45 Miscellaneous Exhibit -- exhibit99-45 HTML 28K 47: EX-99.46 Miscellaneous Exhibit -- exhibit99-46 HTML 454K 48: EX-99.47 Miscellaneous Exhibit -- exhibit99-47 HTML 29K 49: EX-99.48 Miscellaneous Exhibit -- exhibit99-48 HTML 114K 50: EX-99.49 Miscellaneous Exhibit -- exhibit99-49 HTML 33K 6: EX-99.5 Miscellaneous Exhibit -- exhibit99-5 HTML 1.56M 51: EX-99.50 Miscellaneous Exhibit -- exhibit99-50 HTML 33K 52: EX-99.51 Miscellaneous Exhibit -- exhibit99-51 HTML 49K 53: EX-99.52 Miscellaneous Exhibit -- exhibit99-52 HTML 31K 54: EX-99.53 Miscellaneous Exhibit -- exhibit99-53 HTML 44K 55: EX-99.54 Miscellaneous Exhibit -- exhibit99-54 HTML 31K 56: EX-99.55 Miscellaneous Exhibit -- exhibit99-55 HTML 297K 57: EX-99.56 Miscellaneous Exhibit -- exhibit99-56 HTML 101K 58: EX-99.57 Miscellaneous Exhibit -- exhibit99-57 HTML 33K 59: EX-99.58 Miscellaneous Exhibit -- exhibit99-58 HTML 33K 60: EX-99.59 Miscellaneous Exhibit -- exhibit99-59 HTML 37K 7: EX-99.6 Miscellaneous Exhibit -- exhibit99-6 HTML 499K 61: EX-99.60 Miscellaneous Exhibit -- exhibit99-60 HTML 34K 62: EX-99.61 Miscellaneous Exhibit -- exhibit99-61 HTML 31K 63: EX-99.62 Miscellaneous Exhibit -- exhibit99-62 HTML 33K 64: EX-99.63 Miscellaneous Exhibit -- exhibit99-63 HTML 35K 65: EX-99.64 Miscellaneous Exhibit -- exhibit99-64 HTML 33K 66: EX-99.65 Miscellaneous Exhibit -- exhibit99-65 HTML 36K 67: EX-99.66 Miscellaneous Exhibit -- exhibit99-66 HTML 37K 68: EX-99.67 Miscellaneous Exhibit -- exhibit99-67 HTML 37K 69: EX-99.68 Miscellaneous Exhibit -- exhibit99-68 HTML 31K 70: EX-99.69 Miscellaneous Exhibit -- exhibit99-69 HTML 37K 8: EX-99.7 Miscellaneous Exhibit -- exhibit99-7 HTML 155K 71: EX-99.70 Miscellaneous Exhibit -- exhibit99-70 HTML 33K 72: EX-99.71 Miscellaneous Exhibit -- exhibit99-71 HTML 30K 73: EX-99.72 Miscellaneous Exhibit -- exhibit99-72 HTML 32K 74: EX-99.73 Miscellaneous Exhibit -- exhibit99-73 HTML 177K 75: EX-99.74 Miscellaneous Exhibit -- exhibit99-74 HTML 37K 76: EX-99.75 Miscellaneous Exhibit -- exhibit99-75 HTML 35K 77: EX-99.76 Miscellaneous Exhibit -- exhibit99-76 HTML 159K 78: EX-99.77 Miscellaneous Exhibit -- exhibit99-77 HTML 160K 79: EX-99.78 Miscellaneous Exhibit -- exhibit99-78 HTML 42K 80: EX-99.79 Miscellaneous Exhibit -- exhibit99-79 HTML 35K 9: EX-99.8 Miscellaneous Exhibit -- exhibit99-8 HTML 75K 81: EX-99.80 Miscellaneous Exhibit -- exhibit99-80 HTML 35K 82: EX-99.81 Miscellaneous Exhibit -- exhibit99-81 HTML 588K 83: EX-99.82 Miscellaneous Exhibit -- exhibit99-82 HTML 46K 84: EX-99.83 Miscellaneous Exhibit -- exhibit99-83 HTML 50K 85: EX-99.84 Miscellaneous Exhibit -- exhibit99-84 HTML 47K 86: EX-99.85 Miscellaneous Exhibit -- exhibit99-85 HTML 35K 87: EX-99.86 Miscellaneous Exhibit -- exhibit99-86 HTML 355K 88: EX-99.87 Miscellaneous Exhibit -- exhibit99-87 HTML 130K 89: EX-99.88 Miscellaneous Exhibit -- exhibit99-88 HTML 33K 90: EX-99.89 Miscellaneous Exhibit -- exhibit99-89 HTML 33K 10: EX-99.9 Miscellaneous Exhibit -- exhibit99-9 HTML 32K 91: EX-99.90 Miscellaneous Exhibit -- exhibit99-90 HTML 37K 92: EX-99.91 Miscellaneous Exhibit -- exhibit99-91 HTML 35K 93: EX-99.92 Miscellaneous Exhibit -- exhibit99-92 HTML 39K 94: EX-99.93 Miscellaneous Exhibit -- exhibit99-93 HTML 35K 95: EX-99.94 Miscellaneous Exhibit -- exhibit99-94 HTML 59K 96: EX-99.95 Miscellaneous Exhibit -- exhibit99-95 HTML 35K 97: EX-99.96 Miscellaneous Exhibit -- exhibit99-96 HTML 42K 98: EX-99.97 Miscellaneous Exhibit -- exhibit99-97 HTML 31K 99: EX-99.98 Miscellaneous Exhibit -- exhibit99-98 HTML 39K 100: EX-99.99 Miscellaneous Exhibit -- exhibit99-99 HTML 48K
| Cannex Capital Holdings Inc. Exhibit 99.122 - Filed by newsfilecorp.com |
Cannex Reports Financial Results for Fourth Quarter of Fiscal 2019
Cannex continues with strong operating performance from its
tenant in Washington State, NWCS,
while investing for future growth;
4Front combination remains on track for July 31 close
Vancouver, BC, June 28, 2019 – Cannex Capital Holdings Inc. (CSE: CNNX; OTCQB: CNXXF) (“Cannex” or the “Company”) is pleased to report financial results for its fourth quarter of fiscal 2019 (“Q4 2019”) ended April 30, 2019. Owing to the restructuring work being done as part of the planned business combination (the “Transaction”) with 4Front Holdings LLC (“4Front”), Cannex has elected to change its fiscal year end to July 31, and therefore Cannex’s fiscal 2019 will be five fiscal quarters concluding on July 31. All financial amounts are in United States dollars. Cannex’s financial results have been prepared in accordance with International Financial Reporting Standards (“IFRS”).
Management Discussion and Recent
Developments
Please refer to Cannex’s “Management’s Discussion and
Analysis: 12 Months Ended April 30, 2019” (the “MD&A”) for a
comprehensive overview of the period, available at www.sedar.com.
“Cannex is pleased to report continued strong operational performance in Washington state,” said Anthony Dutton, CEO of Cannex. “Washington is a key operating, branding, and product development component for Cannex and is a foundational building block of our long-term strategy. Further to our recent disclosures regarding the business combination with 4Front, Cannex expects to close the Transaction on or before July 31, 2019 and looks forward to leveraging its operational expertise into emerging rapidly growing jurisdictions.”
As the Company reported on April 26, 2019, securityholders of Cannex voted overwhelmingly in favour of the Transaction with 4Front at a special meeting of securityholders held on April 18, 2019. Specifically, the Transaction was approved by 99.97% of Cannex common shares voted at the meeting, 100% of holders of Class A convertible restricted voting shares of Cannex, and 100% of the holders of senior convertible notes of Cannex who voted at the Meeting. In the same news release, the Company also announced that the Canadian Securities Exchange (the “CSE”) has conditionally approved the resulting issuer for listing and allowed Cannex to resume trading.
“I am very happy with my team’s performance and continued growth. I am most impressed with their readiness to take on leadership roles in new markets like Massachusetts and Illinois to replicate the success they’ve helped drive in Washington. We are at a point where we will immediately bring very strong operational capabilities to every new market we have on our plate after the 4Front Transaction closes and, with 4Front’s recent closing of its $50,000,000 real estate funding, we have the capital support to penetrate these new markets with scale,” said Leo Gontmakher, COO of Cannex.
Additionally, in June 2019, Cannex closed the acquisition of San Diego, California-based Pure Ratios Holdings, Inc. (“Pure Ratios”), a wellness product company which develops wellness products that combine cannabinoids with traditional medicine ingredients. Their CBD products are sold nationally, while their THC products are produced under license by licensed cannabis operators in California and other states.
Financial Highlights
Below outlines the key
financial metrics for Cannex’s Q4 2019. A more detailed discussion can be found
in the Company’s financial statements and MD&A filed on www.sedar.com. Due to the change in year end, the
comparable fourth quarter of fiscal 2018 was the four-month period January 1,
2018 to April 30, 2018 (referred to as the “comparative period”).
| Cannex Capital | www.cannexcapital.com | info@cannexcapital.com | 604 628 9338 |
Revenues
Revenues were $3,804,286 in Q4 2019,
compared to $4,056,163 for the four-month comparative period (January 1, 2018 to
April 30, 2018), representing a 25% increase in average monthly revenue. Revenue
was generated primarily by way of rental income and packaging sales.
Revenue for the four fiscal quarters ended April 30, 2019, from May 1, 2018 to April 30, 2019, was $13,935,010. Cannex commenced revenue-generating operations around May 1, 2017 and generated $10,279,182 through April 30, 2018 (reported on financial statements covering the calendar period from February 23, 2017 to April 30, 2018, and available online at www.sedar.com). Accordingly, revenue for the 12-month period ended April 30, 2019 was 36% higher than in the corresponding year-earlier period.
Please see Cannex’s financial statements and MD&A on www.sedar.com for a full explanation of Cannex’s financial results for the period.
Net Income
“Over the last fiscal quarter, we
have invested significantly into people in preparation for the closing of the
Transaction – we want to be able to deploy capable teams as quickly as possible
with adequate, centralized support,” said Dave Croom, CFO of Cannex. “When
combined with the Transaction-related costs such as legal and professional
services, we had a near-term reduction in our EBITDA for the period, but seeing
the underlying volume of product our packaging solutions support for Northwest
Cannabis Solutions (“NWCS”), we view this as an investment in future
growth rather than any deficiency in Cannex’s operating business. The large loss
in fair value on derivative liability is related to Cannex’s stock price
appreciating between November 2018 and April 30, 2019, and we don’t consider it
to be relevant in looking at the actual performance of the business.”
Loss for the current period was $48,013,690, as compared to a loss of $2,981,300 for the comparative period. Most of the loss in the current period was attributable to a change in the fair value of a derivative liability associated with the $32,000,000 Gotham Green secured convertible note financing, which occurred in November 2018 (the “GGP Notes”). The GGP Notes convert to Cannex common stock at US$0.83 per share, a 28% premium to the closing price of Cannex stock on the day the secured debt was issued, US$0.65. Because the closing price of Cannex shares on April 30, 2019, was US$1.50, per IFRS rules Cannex had to record a loss in fair value of derivative liability on the GGP Notes of $42,600,000 for Q4 2019. This loss is not a cash expense. For a more complete discussion, please see the section entitled “Note on Net Loss and Derivative Liability” in the MD&A, available on www.sedar.com.
Adjusted EBITDA
Adjusted EBITDA for Q4 2019
was a loss of $631,174, as compared to positive adjusted EBITDA of $1,911,434 in
the comparative period, driven largely by 4Front Transaction costs.
Adjusted EBITDA is a non-Generally Accepted Accounting Principles (“GAAP”) financial measure and accordingly not an earnings measure recognized by IFRS and does not carry standard prescribed significance. Moreover, Cannex’s method for calculating Adjusted EBITDA may differ from that employed by other companies using the same designation. We caution readers that Adjusted EBITDA should not be substituted for determining net income (loss) as an indicator of operating results or as a substitute for cash flows from operating and investing activities.
About Cannex Capital Holdings Inc.
Cannex has
operational expertise in premium indoor cannabis cultivation, extraction,
manufacturing, and branding of cannabis edible and derivative products. Through
its wholly-owned subsidiaries, Cannex leverages this operational expertise to
provide a wide range of services to operating cannabis companies, including real
estate, management, financial, branding and IP licensing. Cannex subsidiary Pure
Ratios is a wellness company focused on formulating products which combine
cannabinoids with traditional and holistic ingredients. Cannex also owns
BrightLeaf Development LLC which holds real estate assets, property leases, brands and intellectual property, and material supply
agreements with Superior Gardens LLC (d/b/a Northwest Cannabis Solutions),
Washington State’s and the Pacific Northwest’s largest full-line cannabis
producer/processor, as well as 7Point Holdings LLC, another Washington State
licensed cannabis producer/processor. Based in Vancouver, BC, Cannex is managed
by a team of experienced industry and capital markets experts who are committed
to aggressive, cost-effective growth.
2
Cannex Capital Holdings Inc.
Anthony Dutton,
CEO
(604) 649-7787
Email: adutton@cannexcapital.com
Website:
www.cannexcapital.com
This news release was prepared by management of Cannex, which takes full responsibility for its contents. The Canadian Securities Exchange (“CSE”) has not reviewed and does not accept responsibility for the adequacy of this news release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Cannex’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements related to future developments and the business and operations of Cannex, developments with respect to legislative developments in the United States, the proposed closing date of the Transaction, and other statements of fact.
Although Cannex has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US Federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Cannex disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Cannex does not assume any liability for disclosure relating to any other company mentioned herein.
3
| This ‘40FR12G’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 7/31/19 | None on these Dates | |||
| Filed on: | 7/16/19 | |||
| 6/28/19 | ||||
| 4/30/19 | ||||
| 4/26/19 | ||||
| 4/18/19 | ||||
| 5/1/18 | ||||
| 4/30/18 | ||||
| 1/1/18 | ||||
| 5/1/17 | ||||
| 2/23/17 | ||||
| List all Filings | ||||